A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate and compare the safety, tolerability, and effectiveness of long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who have had multiple episodes of AIDS associated Pneumocystis carinii pneumonia (PCP).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fisons
• Treatments: Pentamidine

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Zidovudine (AZT).

Patients must have:

• AIDS.

• Recovered from their most recent episode of Pneumocystis carinii pneumonia (PCP). Patients must be at least 2 weeks status post therapy for acute PCP.

• Adequate pulmonary function (vital capacity = or > 65 percent of predicted; forced expiratory volume, 1 s = or > 55 percent of total FEV; and corrected pulmonary diffusion capacity > 50 percent of predicted).

• Patients must be free of acute medical problems.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• AIDS-defining opportunistic infection prior to entry such as toxoplasmosis and cryptococcosis.

• Pulmonary Kaposi's sarcoma.

• Asthma poorly controlled by medication.

• Receiving active therapy for tuberculosis.

Concurrent Medication:

Excluded:

• Active therapy for tuberculosis.

Patients with the following are excluded:

• Requiring ongoing active therapy for an opportunistic infection at time of study entry.

• AIDS-defining opportunistic infection prior to study entry such as toxoplasmosis and cryptococcosis.

• Pulmonary Kaposi's sarcoma.

• Unwilling to sign informed consent.

• Asthma poorly controlled by medication.

• Unwilling to cooperate with study procedures.

• Receiving active therapy for tuberculosis.

Prior Medication:

Excluded within 30 days of study entry:

• Antiretrovirals (other than zidovudine (AZT)).

• Immunomodulating agents.

• Corticosteroids.

Prior Treatment:

Excluded within 7 days of study entry:

• Transfusion.

• Patient cannot be transfusion dependent (requiring blood transfusion more than once per month).

Active substance abuse.